Inquiry Basket
CAS No.: 2280998-74-3
Cat No.: BADC-01952
Purity: >98%
4.5 
m-PEG11-COOH is a long PEG linker used in ADC synthesis to increase hydrophilicity and improve pharmacokinetics, enhancing antibody-drug conjugate stability and therapeutic efficacy.
Structure of 2280998-74-3
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
m-PEG11-COOH is a versatile ADC linker intermediate widely used in the design and construction of antibody-drug conjugates (ADCs) and targeted bioconjugation research. As a PEG-based linker, m-PEG11-COOH provides a long, hydrophilic spacer that improves solubility, reduces aggregation, and enhances the pharmacokinetic properties of ADC payloads. Its terminal carboxylic acid group enables efficient conjugation to monoclonal antibodies or ADC cytotoxins through amide bond formation. In ADC linker design, m-PEG11-COOH supports site-specific conjugation strategies, maintaining antibody functionality while facilitating controlled intracellular delivery of therapeutic payloads.
In payload conjugation applications, m-PEG11-COOH is compatible with a broad range of ADC cytotoxins, including DNA-targeting agents, microtubule inhibitors, and other potent therapeutic molecules. The PEG11 spacer enhances linker flexibility and hydrophilicity, reducing steric hindrance and improving the stability of the resulting ADC. The carboxylic acid functional group allows reproducible and selective conjugation under mild conditions, supporting homogeneous ADC construction. Researchers can use m-PEG11-COOH to optimize linker length, improve intracellular payload release, and achieve high-performance ADCs suitable for both preclinical research and industrial-scale production.
From an application perspective, m-PEG11-COOH is widely applied in oncology-focused ADC research, protein bioconjugation studies, and targeted drug delivery systems. Its long PEG chain enhances circulation time, minimizes aggregation, and supports improved pharmacokinetics of ADC payloads, while the terminal carboxyl group provides predictable and controllable conjugation. By integrating m-PEG11-COOH into ADC linker design, developers can construct flexible, stable, and highly soluble linker-payload constructs, enabling tumor-specific delivery and high-performance therapeutic applications in modern ADC development.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-00889 | m-PEG8-COOH | 1093647-41-6 | |
| BADC-01955 | m-PEG10-COOH | 2409969-94-2 | |
| BADC-01145 | m-PEG4-COOH | 67319-28-2 |
#VALUE!
m-PEG11-COOH acts as a hydrophilic spacer in ADCs, improving solubility, reducing aggregation, and enhancing pharmacokinetics. The terminal carboxylic acid enables straightforward conjugation to antibodies via amide bond formation.
10/11/2022
Could you explain how m-PEG11-COOH influences ADC pharmacodynamics?
The PEG11 chain increases molecular flexibility, reduces steric hindrance, and minimizes immune recognition. These properties support improved biodistribution, circulation half-life, and controlled payload release.
17/12/2022
We would like to know which conjugation strategies are suitable for m-PEG11-COOH.
Its carboxyl group is compatible with standard amide coupling chemistries, allowing efficient attachment to antibody lysine residues. This enables reproducible ADC synthesis with predictable drug-antibody ratios.
12/9/2016
Good morning! Is m-PEG11-COOH compatible with various payload types?
Yes, m-PEG11-COOH supports conjugation with diverse small-molecule cytotoxins, fluorescent probes, and imaging agents. Its PEG spacer ensures proper antibody-payload spacing for optimal ADC functionality.
16/2/2016
Dear BOC Sciences, which analytical documents are available for m-PEG11-COOH to support quality verification?
m-PEG11-COOH is accompanied by standard analytical documentation including NMR spectra, mass spectrometry data, and chromatographic profiles. These documents allow verification of molecular weight and functional group integrity, supporting reliable usage in ADC linker synthesis.
19/3/2019
— Dr. Michael Scott, Senior Chemist (USA)
m-PEG11-COOH demonstrated excellent solubility and facilitated smooth PEGylation.
12/9/2016
— Ms. Emily Fischer, Biochemist (Germany)
Lot-to-lot reproducibility was excellent, enabling consistent multi-step synthesis.
19/3/2019
— Dr. Thomas White, ADC Scientist (UK)
High conjugation efficiency and minimal side products were observed.
16/2/2016
— Dr. Isabelle Laurent, Medicinal Chemist (France)
The reagent integrated seamlessly into our ADC linker workflows.
10/11/2022
— Dr. Helena Meyer, Research Scientist (Germany)
m-PEG11-COOH supported innovative linker architectures enhancing ADC solubility.
— Prof. Emma Clarke, Protein Chemist (UK)
m-PEG11-COOH from BOC Sciences facilitated smooth PEGylation of our therapeutic proteins. The product quality and solubility were outstanding.
17/12/2022
m-PEG11-COOH
Required fields are marked with *
m-PEG11-COOH
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
